TRPV1 is a sensory transduction channel that mediates thermal nociception and some aspects of pathological pain. In this issue of Neuron, Gibson et al. report that TRPV1 also plays important roles in hippocampal synaptic plasticity, presenting a potential challenge for TRPV1-targeted therapeutics for the treatment of pain.
Transient receptor potential vanilloid 1 (TRPV1) is a nonselective cation channel activated by noxious heat, protons, several endogenous lipid-derived signaling molecules, and capsaicin, the pungent compound from chili peppers (Levine and Alessandri-Haber, 2007) . TRPV1 is present on peripheral sensory nerve endings where it is thought to be a molecular sensor of noxious heat. Although TRPV1 is normally activated at temperatures much higher than body temperature, its activation threshold shifts downward during inflammation. This sensitization of the channel underlies inflammation-induced hypersensitivity to warm temperatures that are normally innocuous, a phenomenon that anyone with a sunburn trying to take a warm shower can surely appreciate. Recent evidence indicates that TRPV1 is also expressed in the central nervous system (CNS), although its function in different brain regions is not entirely clear (Steenland et al., 2006) . In this issue of Neuron, Gibson and colleagues report that TRPV1 is also a key mediator of synaptic plasticity in the hippocampus (Gibson et al., 2008) , raising intriguing questions about hippocampal function and challenging the feasibility of targeting TRPV1 for the treatment of pain.
One of the most studied forms of synaptic plasticity is the use-dependent potentiation of excitatory synapses onto the pyramidal cells in area CA1 of the hippocampus (Kullmann and Lamsa, 2007) . This long-term potentiation (LTP) is robustly produced by high-frequency stimulation (HFS) of afferents in stratum radiatum (s. radiatum). While HFS produces LTP in pyramidal cells, it simultaneously decreases the strength of excitatory synapses from the same afferents onto inhibitory interneurons found within s. radiatum (McMahon and Kauer, 1997) . Gibson and colleagues sought to elucidate the mechanisms underlying this form of interneuron long-term depression (iLTD). NMDA receptors (NMDAR) are molecular coincidence detectors that underlie many forms of synaptic plasticity. Interestingly, the NMDAR antagonist D-AP5 had no effect on iLTD. Moreover, NMDAR-mediated EPSCs also showed LTD, suggesting that iLTD is mediated by reduced glutamate release from the presynaptic terminal. This conclusion is supported by additional observations that HFS increased the paired-pulse ratio, increased the failure rate of evoked EPSCs, and altered the coefficient of variation of EPSC amplitude.
All of these results point toward a presynaptic mechanism for iLTD, begging the question, which receptors initiate which retrograde messengers to signal presynaptic changes? Application of an mGlu1 antagonist completely abolished iLTD. mGlu1 is coupled to endocannabinoid signaling in other systems, so it was a likely possibility that postsynaptic mGlu1 activation would result in endocannabinoid release across the synapse and activation of presynaptic CB1 receptors. One CB1 receptor antagonist, SR141716A, eliminated iLTD, while AM251, another CB1 antagonist, had no effect. This surprising, if not troubling, result prompted further investigation. Gibson and colleagues performed an occlusion experiment to see whether activation of CB1 receptor would prevent HFS-induced iLTD. The CB1 receptor agonist, WIN55,212-2, did not prevent HFS-induced iLTD, indicating that CB1 receptors are probably not involved in iLTD. This presented a puzzling situation in which pharmacological agents that are purported to have the same target gave disparate results. In these situations, one might question the selectivity of one or both of the drugs under consideration. Indeed, a recent report indicated that SR141716A may also antagonize TRPV1 (De Petrocellis et al., 2001) , prompting Gibson and colleagues to revise their hypothesis to include TRPV1 as a potential signaling component. Using an elegant combination of pharmacology and genetics, the authors show that TRPV1 is necessary and sufficient for iLTD. They also provide evidence supporting a model in which an endogenous ligand of TRPV1, 12-(S)-HPETE, is synthesized postsynaptically and then acts on presynaptic TRPV1 to produce iLTD.
In one experiment, Gibson and colleagues addressed the possible role of TRPV1 in pyramidal cell synapses. They found that neither capsaicin nor 12-(S)-HPETE affect the synaptic strength of CA3-CA1 pyramidal cell synapses. This experiment and the iLTD experiments demonstrate that excitatory synapses onto pyramidal cells are functionally very different than excitatory synapses onto interneurons, despite the fact that they arise from the same set of afferents. Interestingly, a previous study found that capsaicin decreased evoked EPSCs in CA1 pyramidal neurons (Hajos and Freund, 2002) , which seems to contradict the findings of Gibson and colleagues. However, Hajos and Freund used a 10-fold higher concentration of capsaicin and maintained their slice preparation at a higher temperature during their recordings. Both alterations would significantly increase TRPV1 activation compared to the experimental conditions used by Gibson and colleagues. Taken together, it appears that one of the functional differences between the synapses onto CA1 pyramidal cells and the synapses onto CA1 interneurons is the relative sensitivity of the two synapses to TRPV1 activation. At 10 mM capsaicin, CA1 pyramidal cell evoked EPSC amplitude is decreased (Hajos and Freund, 2002) . Gibson and colleagues report that there are no changes in EPSC amplitude following 1 mM capsaicin. Nevertheless, Gibson and colleagues report that this concentration of capsaicin elicits TRPV1-mediated currents in CA1 and CA3 pyramidal cells under their recording conditions. This is consistent with several other studies reporting the expression of TRPV1 mRNA and protein in pyramidal cells (Cristino et al., 2006; Mezey et al., 2000; Toth et al., 2005) . Interestingly, without any TRPV1 activation, as in TRPV1 À/À mice, HFS-induced LTP is reduced (Marsch et al., 2007) . This last piece of evidence argues for a model in which TRPV1 is actively modulating synaptic strength in two opposing directions-perhaps decreasing presynaptic glutamate release while increasing available AMPA receptors postsynaptically. Strong activation of TRPV1 may activate both potentiating and depressing mechanisms, but synaptic depression is more robust or is somehow upstream of the accompanying potentiating mechanism. Weaker TRPV1 activation may only engage the potentiating mechanisms, since TRPV1 À/À mice have reduced LTP. Regardless, further study will be required to clarify the role of TRPV1 in excitatory synapses onto pyramidal cells. It is certainly possible that TRPV1 does not play a role at pyramidal cell synapses. If this is the case and if the only function of TRPV1 in hippocampus is to modulate iLTD, future studies could utilize TRPV1 agonists and antagonists to determine the behavioral relevance of iLTD and the function of s. radiatum interneurons. This study by Gibson and colleagues extends previous findings by the same group concerning iLTD. Prior work showed that this form of plasticity is not synapse specific, since HFS of one set of afferents induced synaptic depression in a second independent set of afferents that did not receive HFS (McMahon and Kauer, 1997 ). In the current study, Gibson and colleagues provide evidence for a presynaptic locus of iLTD. Since iLTD is presynaptically mediated but not synapse specific, it is possible that 12-(S)-HPETE diffuses from stimulated synapses to unstimulated synapses on the same interneuron where it could activate TRPV1 and reduce the strength of those synapses. It is also possible that other signaling molecules within interneurons, such as Ca 2+ or activated kinases, diffuse inside the dendrite to unstimulated synapses where they initiate the synthesis of 12-(S)-HPETE. This second model would require less 12-(S)-HPETE production overall, allowing for specific control of interneuron synapses without ''spillover'' effects onto neighboring cells' synapses. Either way, iLTD represents a biological balancing act that requires widespread broadcasting of signals to unstimulated synapses while maintaining some degree of cellular specificity. Future studies into the mechanisms behind this balancing act will add to our knowledge of the computational functions performed by hippocampal circuits. The results from this study have important implications for the development of drugs targeting TRPV1. There is an immense body of work implicating TRPV1 in acute nociception, a normal physiological process, as well as in pathological pain states, including neuropathic and inflammatory pain (Levine and Alessandri-Haber, 2007 ). As such, there are several TRPV1 antagonists in various stages of drug development for the treatment of pain (Szallasi et al., 2007) . Although TRPV1 is most strongly expressed in sensory neurons, it has become clear that it is functionally expressed in many other tissues throughout the body, including the central nervous system (Steenland et al., 2006; Szallasi et al., 2007) . These observations, as well as the results from Gibson and colleagues, cloud the prospects of TRPV1-targeted analgesics. If TRPV1 is important in hippocampal synaptic plasticity, as this study suggests, then systemic TRPV1 antagonists may interfere with many processes thought to rely on hippocampal synaptic plasticity, such as learning and memory. Indeed, TRPV1 À/À mice, which lack TRPV1 in all tissues, have reduced anxiety and diminished fear conditioning (Marsch et al., 2007) . Therefore, drugs targeting TRPV1 may adversely affect cognitive function, representing a potential roadblock to the usage of TRPV1 antagonists to treat pain.
However, there is a silver lining to this cloud. The expression pattern of TRPV1 in the CNS includes expression in structures shown to be involved in pain processing, such as the periaqueductal gray (Steenland et al., 2006) . Targeting these receptors with TRPV1 antagonists that act both centrally and peripherally actually produced greater analgesia than antagonists thought to primarily act in the periphery (Cui et al., 2006) . A systemically acting TRPV1 antagonist would therefore act at multiple anatomic loci at the same time to achieve analgesia. Moreover, if TRPV1 antagonists cause adverse side effects by interfering with CNS function, other agents with lower CNS penetration could still be systemically administered. Of course, these antagonists could also be locally applied. In other systems within the CNS, TRPV1 receptor expression may provide the opportunity for additional uses of TRPV1-targeted drugs. For example, TRPV1-mediated iLTD may contribute to epileptogenesis (see Discussion of Gibson and colleagues). Regardless of the uncertain future of TRPV1-targeted therapeutics, studies like that of Gibson and colleagues are important not only for drug development but also for expanding our knowledge of synaptic function.
By distinguishing groups of dopamine neurons that differ in their projection patterns and intrinsic properties, Lammel and colleagues report in this issue of Neuron that mesocorticolimbic dopamine neurons of the ventral tegmental area (VTA) form a distinct subclass of dopamine cells.
Dysregulation of dopamine systems underlies a variety of disorders, ranging from Parkinson's disease to drug addiction. Understanding the physiology of these dopamine neural networks is a key first step in determining the etiology of these diseases. In the midbrain, dopaminergic neurons are broadly classified anatomically into the Substantia Nigra pars compacta (SNc) (A9) and the ventral tegmental area (VTA) (A10). Projections from different dopamine cells innervate the striatum, cortical regions such as the prefrontal cortex, and limbic structures such as the nucleus accumbens (NAc) and amygdala. In very broad terms, cells of the VTA innervate mesocorticolimbic structures and cells of the SNc innervate the dorsal striatum. This is an oversimplification since substantial anatomical overlap of these networks is known to exist (Bjorklund and Dunnett, 2007; Ikemoto, 2007) .
To identify dopamine cells that form specific networks, it is important (1) to be able to relate the targets of individual dopamine cells to specific behaviors (Ikemoto, 2007) , and (2) to catalog the properties of the individual groups of dopamine cells that project to those targets. Recent work has begun to assign intrinsic and pharmacological properties to dopamine cells according to the targets they innervate (Ford et al., 2006; Liss et al., 2005; Margolis et al., 2006) . However, to date these studies have not provided an overall explanation of how the intrinsic properties of dopamine cells may mediate differences in firing patters of individual cells and the release of dopamine in various projection areas (Garris and Wightman, 1994) .
In this issue of Neuron, Lammel et al. (2008) make an important step by examining how the properties of individual dopamine cells relate to the neural networks they reside within. By making use of retrograde tracers, they identify specific groups of projecting dopamine neurons. Through an exhaustive study, combining anatomical, electrophysiological, immunohistochemical, and laser-dissected individual mRNA-expression profiling based examinations, they identify two populations of mesocorticolimbic dopamine cells that segregate according to their projection targets.
The cell bodies of dopamine neurons that project to the medial prefrontal cortex (mPFC), medial accumbens shell, accumbens core, or amygdala originate in the medial posterior portion of the VTA. Dopamine cells that projected to the lateral shell of the NAc were only observed in more lateral portions of the VTA, partially overlapping with SNc cells that project to the dorsal striatum. These two groups of dopamine cells (mPFC, accumbens medial shell, and core and amygdala-projecting cells versus lateral shell and striatal-projecting cells) also varied in their expression levels of mRNA for key markers of dopamine cells. Markers included mRNA for tyrosine hydroxylase (TH), dopamine transporter (DAT), and vesicular monoamine transporter 2 (VMAT2). The abundance of these markers covaried in the two groups of neurons, being lower in the group of neurons located in the medial aspect of the VTA and higher in neurons that projected to the lateral aspect of the NAc shell and dorsal striatum. Thus, two broad groups of dopamine cells were defined based on both anatomical and biochemical characteristics.
The two groups of dopamine cells were further distinguished based on the intrinsic electrophysiological properties. Classical electrical properties of dopamine neurons in brain slice preparations include slow pacemaker firing, the presence of HCN
